Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9204-0530 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| NNC9204-0530 / Placebo and Liraglutide 1.8 | EXPERIMENTAL | - |
| NNC9204-0530 /Placebo and Liraglutide 3.0 | ACTIVE_COMPARATOR | - |
| NNC9204-0530 | EXPERIMENTAL | Dose-escalation within the cohort before reaching final dose |
| Placebo | PLACEBO_COMPARATOR | - |
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC9204-0530 | DRUG | Once-daily subcutaneous (s.c., under the skin) administration. |
| liraglutide | DRUG | Once-daily subcutaneous (s.c., under the skin) administration. |
| placebo | DRUG | Once-daily subcutaneous (s.c., under the skin) administration |
Inclusion Criteria: * Body mass index between 25.0 and 39.9 kg/m\^2 (both inclusive) at screening. * Male or female, age between 18 and 55 years (both inclusive) at the time of signing informed consent Exclusion Criteria: * Any clinically significant weight change (equal or above 5% self-reported...
NNC9204-0530 is an investigational small molecule being developed for metabolism and nutrition disorders, specifically obesity. It is being studied in overweight or obese individuals to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
NNC9204-0530 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to investigate the drug's effects in overweight and obese subjects, including its use alone and in combination with liraglutide.
NNC9204-0530 is in Phase 1 clinical development. All three clinical trials for this drug have been completed, with a total enrollment of 398 participants. The trials were randomized, double-blind, and placebo-controlled, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics in overweight or obese individuals.
NNC9204-0530 has been studied in three completed Phase 1 trials: NCT02235961, which investigated single doses alone and with liraglutide in overweight to obese healthy male subjects; NCT02835235, which studied multiple doses in overweight or obese male and female subjects; and NCT02870231, which investigated multiple doses in combination with liraglutide in overweight or obese subjects.
No, NNC9204-0530 is not the same as liraglutide. NNC9204-0530 is an investigational small molecule being studied for obesity, while liraglutide is a separate medication. In clinical trials, NNC9204-0530 has been tested both alone and in combination with liraglutide to evaluate their combined effects in overweight or obese individuals.